These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


152 related items for PubMed ID: 16504668

  • 1. Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients.
    Niemczyk M, Nowak M, Pilecki T, Wyzgał J, Ziółkowski J, Zygier D, Paczek L.
    Transplant Proc; 2006; 38(1):74-7. PubMed ID: 16504668
    [Abstract] [Full Text] [Related]

  • 2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 3. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Nov 15; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 5. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 15; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 6. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
    van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L.
    Transplantation; 2003 Jun 27; 75(12):1934-9. PubMed ID: 12829890
    [Abstract] [Full Text] [Related]

  • 7. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA, International Sirolimus Study Group.
    Transplantation; 2009 Oct 27; 88(8):1010-8. PubMed ID: 19855247
    [Abstract] [Full Text] [Related]

  • 8. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 27; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 9. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
    Transpl Int; 2007 Oct 27; 20(10):875-83. PubMed ID: 17854445
    [Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM, Andrés A, Dominguez-Gil B, Arriola M, Gutiérrez MJ, Hernández E, Ortuño T, Praga M.
    Transplant Proc; 2005 Nov 27; 37(9):3738-42. PubMed ID: 16386523
    [Abstract] [Full Text] [Related]

  • 12. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 27; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 14. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Clin Transplant; 2007 Mar 27; 21(3):330-6. PubMed ID: 17488381
    [Abstract] [Full Text] [Related]

  • 15. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 27; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 16. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
    Tellis V, Schechner R, Mallis M, Rosegreen S, Glicklich D, Moore N, Greenstein S.
    Transplant Proc; 2005 Mar 27; 37(2):906-8. PubMed ID: 15848571
    [Abstract] [Full Text] [Related]

  • 17. Where did we leave off in 2008? Conclusions from the 8th International Symposium.
    Russ G.
    Transplant Proc; 2009 Mar 27; 41(6 Suppl):S27-30. PubMed ID: 19651292
    [Abstract] [Full Text] [Related]

  • 18. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J, Ríos M G, Vignolo A P, Pinochet V C, Schultz M, Humeres A R, Delucchi A, Rius A M, Hepp K J.
    Rev Med Chil; 2008 May 27; 136(5):631-6. PubMed ID: 18769812
    [Abstract] [Full Text] [Related]

  • 19. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov 27; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Kliem V, Fritsche L, Haller H, Suwelack B, Abendroth D, Fornara P, Pietruck F, Frei U, Donauer J, Lison AE, Michel U, Ulbricht B, International MOST Study Group.
    Transplant Proc; 2005 Apr 27; 37(3):1597-600. PubMed ID: 15866683
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.